Table 1.

Changes in laboratory measures during the 20-week studya

ParametersDay 0Day 126
PSA
 PSA (ng/mL)9.36 ± 2.46c15.93 ± 3.45c
 PSA velocity (ng/mL/mo)b1.64 ± 0.421.24 ± 0.84
 PSADT (mo)b13.5 ± 2.436.7 ± 15.5
Lipids
Overall
 Total cholesterol (mg/dL)172 ± 9169 ± 7
 HDL (mg/dL)50 ± 450 ± 4
 LDL (mg/dL)104 ± 8103 ± 6
 Triglycerides (mg/dL)130 ± 11139 ± 12
Hypercholesterolemic
 Total cholesterol (mg/dL)229 ± 10c207 ± 7c
 HDL (mg/dL)59 ± 957 ± 8
 LDL (mg/dL)150 ± 9c132 ± 9c
 Triglycerides (mg/dL)147 ± 23153 ± 26
Endocrine
 hGH (ng/mL)1.16 ± 0.291.02 ± 0.31
 IGF (ng/mL)121.4 ± 6.5125.2 ± 7.2
 IGFBP-3 (μg/mL)3.36 ± 0.81c3.51 ± 0.87c
 IGF1:IGFBP-3 ratio36.2 ± 0.935.5 ± 0.8
 Leptin (ng/mL)12.96 ± 2.113.51 ± 2.0

Abbreviations: PSADT, PSA-doubling time; HDL, high-density lipoprotein; LDL, low-density lipoprotein; hGH, human growth hormone; IgF, insulin-like growth hormone; IgFBP-3, insulin-like growth hormone–binding protein.

  • aMean ± SD (n = 25, men completed study).

  • bDay 0 (PSA values collected before but not including day 0); day 126 (PSA from enrollment to and including day 126).

  • cSignificance (P ≤ 0.05) was determined using ANOVA.